|
M
Mon
|
T
Tue
|
W
Wed
|
T
Thu
|
F
Fri
|
S
Sat
|
S
Sun
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
1 event,
–
Developability assessment of biologics and formulation of novel molecules Shahid Uddin, PhD, MBA, Senior Director of Drug Product, Formulation & Stability within the CMC department at Immunocore, UK It’s vital to ensure appropriate assessment of molecules at the early research phase is carried out to risk mitigate movement into the development phase. This ensures the best risk ... Read more |
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
1 event,
Nanomedicine to Tackle Unmet Medical Needs in CNS Disorders Sabina Quader, Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, Kawasaki, Kanagawa 210-0821 Japan The brain is undoubtedly the body's most essential and intricate organ, and brain disorders are closely tied to this intricacy. Categorized as "CNS diseases," a wide range of brain-related conditions - ... Read more |
0 events,
|
1 event,
–
Semi-synthetic nucleosomes to stabilize and image enzyme-chromatin interactions Carlos Moreno Yruela, Researcher in Chemical Biology, EPFL, Switzerland Chromatin structure regulates gene expression and is tightly controlled by histone post-translational modifications. SIRT7 is a histone lysine deacylase found to maintain oncogenic gene expression profiles supporting tumor growth and metastasis. Interestingly, the activity of SIRT7 is fully ... Read more |
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|